The FDA cleared a new molecular diagnostic test from Roche that detects both bacterial vaginosis and Candida vaginitis from a single vaginal swab. The cobas BV/CV assay received 510(k) clearance on July 24, 2026, and is intended for professional laboratories under a clinician’s order.
It uses real-time polymerase chain reaction technology to identify bacteria and yeast species causing these infections. The method provides faster, more accurate results than syndromic evaluation alone.
Overlapping symptoms complicate diagnosis
Bacterial vaginosis and Candida vaginitis rank among the most common causes of vaginal symptoms in the U.S. Both conditions often produce similar signs, such as discharge, odor, and irritation. The Centers for Disease Control and Prevention estimates nearly all women will experience at least one vaginal infection during their lives, creating ongoing diagnostic challenges.
Related: User Reports Being Blocked Without Explanation
The assay aligns with CDC’s STI Treatment Guidelines (2021, most recently reviewed 2025), which do not call for Candida speciation before first-line therapy is initiated. Additional speciation or susceptibility testing becomes relevant only in cases of persistent or recurrent CV, specifically 3 or more symptomatic episodes in a year or a documented failure of first-line treatment.
The test detects DNA targets for bacteria associated with bacterial vaginosis, including Gardnerella vaginalis, Atopobium vaginae, and Lactobacillus species. It also identifies six Candida species linked to Candida vaginitis: C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, and C. dubliniensis.
Single swab simplifies testing workflow
The cobas BV/CV assay requires a vaginal swab collected by a clinician or through self-collection in a healthcare setting. The same sample works for additional testing, including Roche’s cobas CT/NG for Chlamydia trachomatis and Neisseria gonorrhoeae, and cobas TV/MG for Trichomonas vaginalis and Mycoplasma genitalium.
This compatibility may reduce the need for multiple sample collections, especially in patients with overlapping symptoms. Misdiagnosis based on symptoms alone remains common, and a single-swab approach could improve efficiency in clinical labs.
Related: New Guidelines for Hospital Nausea Treatment Released
Roche will expand the assay’s availability to the cobas 5800 system later this year under the FDA’s Reagent Replacement and Instrument Family Policy. No exact launch date was provided.
While the test offers potential efficiency gains, its real-world impact depends on adoption by labs and clinicians.
The CDC’s 2025 guidelines note most Candida vaginitis cases can be treated without speciation. For recurrent infections, identifying the exact species may help guide targeted therapy.
